Ribupatide
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Completed · Enrollment 249
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment group A | n/r | n/r | n/r | n/r |
| Treatment group B | n/r | n/r | n/r | n/r |
| Treatment group C | n/r | n/r | n/r | n/r |
| Treatment group D | n/r | n/r | n/r | n/r |
| Treatment group E | n/r | n/r | n/r | n/r |
| Treatment group F | n/r | n/r | n/r | n/r |
| Treatment group G | n/r | n/r | n/r | n/r |
| Treatment group H | n/r | n/r | n/r | n/r |
Not shown
- Treatment group A: endpoint not reported
- Treatment group B: endpoint not reported
- Treatment group C: endpoint not reported
- Treatment group D: endpoint not reported
- Treatment group E: endpoint not reported
- Treatment group F: endpoint not reported
- Treatment group G: endpoint not reported
- Treatment group H: endpoint not reported